Abcam, ab261825, Human TNFSF10 (TRAIL) knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
TNFSF10 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1,
Antibiotic resistance:Puromycin 1µg/mL,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TNFSF10, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TRAIL also known as TNF-related apoptosis-inducing ligand plays an important role in inducing apoptosis. This protein has a mass of around 32 kDa and is expressed across various tissues including immune cells. TRAIL interacts with specific receptors on the cell surface to initiate a signaling cascade that results in programmed cell death. It is an attractive therapeutic target because of its selective ability to induce apoptosis in cancer cells while sparing most normal cells.
Biological function summary
TRAIL's function extends beyond inducing cell death. It is an important member of the tumor necrosis factor (TNF) superfamily which regulates immune responses and inflammation. TRAIL can form a homotrimeric complex allowing it to bind effectively to death receptors on target cells specifically DR4 and DR5 triggering a series of downstream signaling events. This interaction is significant in modulating immune surveillance and tumor suppression.
Pathways
TRAIL is integral to both intrinsic and extrinsic apoptosis pathways. Through these pathways TRAIL is closely related to FADD and caspase-8 which are important for apoptosis induction. The extrinsic pathway involves binding to TRAIL death receptors leading to DISC formation while the intrinsic pathway involves mitochondrial events mediated by members of the Bcl-2 protein family.
TRAIL has a significant connection with cancer and autoimmune diseases. TRAIL plays a dual role in cancer where it acts as a tumor suppressor but can also promote tumor progression if cancer cells become resistant to its effects. In cancer TRAIL's interaction with proteins like FLIP can alter the apoptotic potential of the cells. In autoimmune diseases TRAIL's dysregulation can contribute to tissue damage due to increased immune activity highlighting its complex role in maintaining immune balance.